Other research analysts also recently issued reports about the company. Royal Bank Of Canada reiterated a buy rating and issued a $138.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 12th. UBS AG reissued a buy rating and set a $148.00 price objective (up from $136.00) on shares of Johnson & Johnson in a research note on Wednesday, July 19th. Zacks Investment Research raised shares of Johnson & Johnson from a hold rating to a buy rating and set a $148.00 price target for the company in a research report on Thursday, July 27th. Credit Suisse Group reaffirmed a buy rating on shares of Johnson & Johnson in a research report on Friday, August 4th. Finally, Cowen and Company set a $147.00 price target on shares of Johnson & Johnson and gave the stock a buy rating in a research report on Thursday, August 24th. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson currently has a consensus rating of Hold and an average target price of $143.70.
Johnson & Johnson (JNJ) traded down $0.87 during mid-day trading on Monday, hitting $138.00. 4,112,134 shares of the stock were exchanged, compared to its average volume of 5,903,571. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $144.35. The firm has a market cap of $373,080.00, a P/E ratio of 19.54, a price-to-earnings-growth ratio of 2.83 and a beta of 0.82.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.80 by $0.10. The firm had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.68 EPS. equities research analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/johnson-johnson-jnj-stock-rating-upgraded-by-vetr-inc/1744011.html.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.43%. Johnson & Johnson’s payout ratio is 58.33%.
Several institutional investors have recently added to or reduced their stakes in JNJ. State Street Corp raised its holdings in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% in the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares during the last quarter. Janus Henderson Group PLC grew its position in Johnson & Johnson by 717.9% in the 2nd quarter. Janus Henderson Group PLC now owns 3,748,008 shares of the company’s stock worth $495,837,000 after purchasing an additional 3,289,763 shares during the last quarter. Vanguard Group Inc. lifted its holdings in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after acquiring an additional 3,023,110 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in shares of Johnson & Johnson by 47.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock worth $1,054,433,000 after acquiring an additional 2,581,562 shares during the period. Institutional investors and hedge funds own 65.93% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with our FREE daily email newsletter.